A drug container closure for mounting on an open-topped drug container to form a ready-to-use drug reconstitution assemblage for use with a needleless syringe. The drug container closure includes a drug container stopper for sealing the drug container and a fluid transfer member with an integral needleless syringe connector and a puncturing cannula. The fluid transfer member is manually disposed along a diametric inverted L-shaped track pair from an initial non-puncturing position to a puncturing position. The inverted L-shaped track pair includes one-way snap members to prevent a user returning the fluid transfer member to an earlier position and indicating progress of the user activation.

Liquid drug transfer devices employing manual rotation of a drug vial adapter with respect to a liquid container adapter for dual flow communication step actuation for establishing flow communication between a liquid container containing liquid contents and an initially intact, namely, non-punctured, drug vial. Manual rotation compacts a liquid drug transfer device along a longitudinal device axis for urging a puncturing tip through a drug vial stopper during a drug vial flow communication step for flow communication with a drug vial interior. Manual rotation also executes a liquid container flow communication step for flow communication with a liquid container, therefore establishing flow communication between a drug vial and a liquid container.

An assembly for coupling a drug delivery device to a cartridge is disclosed. Optionally the assembly includes a coupling, for example a cannula, having one end extending toward the cartridge. The cartridge is optionally aligned by a guide. Optionally the cartridge has a limited freedom of movement. The coupling is optionally supported by a mount. In some embodiments, the mount is compliant enough that the end of the coupling that extends toward may move to said limited freedom of movement under a force less than a leak threshold of the connection between the coupler and the cartridge.

An apparatus to preserve liquid from a medicine vial may include a vial coupling member forming a vial coupling member cavity and a container forming a cavity. The apparatus may further include a first fluid pathway forming a first lumen that is in fluid communication with the vial coupling member cavity and the cavity and a second fluid pathway forming a second lumen that is in fluid communication with the vial coupling member cavity and the cavity. The vial coupling member cavity, the cavity, the first lumen, and the second lumen may form a sterile environment that is sealed from contaminants in an ambient environment. The apparatus may include a disengaging member configured to permit the container to disengage from the first fluid pathway and the second fluid pathway while permanently sealing at least one of the first lumen or the second lumen.

An alignment assembly for a cartridge interface of a drug delivery device is disclosed. The assembly optionally includes a coupling for opening fluid communication between the cartridge and the delivery device. For example, the coupling optionally includes a cannula insertable through a septum of the cartridge. The assembly may include a guide for positioning the cartridge and/or an access channel thereof within a first precision of a loaded position. The assembly optionally includes a cartridge engagement fitting (for example a gripping expander sleeve collar) attached to the coupling. Optionally when the cartridge is engaged to the fitting, the coupling is retained in connection with the access channel to within a second precision. The second precision is optionally higher than the first precision. In some embodiments one or more compliant supports movably retain the fitting oriented to engage the cartridge when the access channel is in the loaded position.

A liquid-transfer adapter operatively interposable between an injector and a vial is provided. The liquid-transfer has an injector engaging portion configured for fluidly coupling to an injector and a vial coupling. The vial coupling includes a spike that has a spike axis and a tip portion configured for piercing a septum of a vial. The tip portion includes a plurality of facets that meet each other at one or more edges and at least one of the one or more edges is sloped with respect to the spike axis. The spike defines a channel extending therethrough in fluid communication with the injector engaging portion. A channel opening is defined in at least one of the facets and disposed without interrupting the edges.

In one general aspect, the present disclosure provides a drainage system. The drainage system may include a container having an interior and a mouth, the mouth having an outer surface and an opening. A frangible seal may cover the opening. A cap may be secured to the mouth, and the cap may be in fluid communication with a drainage line. The cap may have an inner surface for engaging with the outer surface of the mouth. The drainage system may further include a retention ring with a collar having an inner surface configured to engage an outer surface of the cap, where the retention ring includes a bead for at least partially concentrating a restriction force provided by the retention ring on an adjacent area of the outer surface of the cap.

A stopper is generally provided in which a hollow shell includes at least one outer layer and an inner layer positioned within the outer layer. The outer layer is formed from a substantially solid polymer while the inner layer is formed from a cold-flowable polymer. The cold-flowable polymer is deformable when an object is inserted therein and is scalable when the object is removed.

Methods for compounding a therapeutic agent for intravenous administration. The method comprise providing a syringe or vial comprising the agent dissolved or pre-dissolved in a carrier at a dose or concentration that is therapeutically effective for a particular patient but is not commercially available at the therapeutically effective dose or concentration or is on the U.S. FDA drug shortage list, and adding the therapeutic agent dissolved in the carrier to an intravenous solution (diluent). The methods exclude reconstituting multiple solid forms of the commercially available agent and combining the reconstituted preparations together, for example, according to traditional compounding procedures at point-of-care pharmacies.

The present invention relates to a buffy coat extraction kit including: a kit body having a cylindrical plasma part that has an internal volume for forming a plasma layer, a cylindrical buffy coat part which extends in the longitudinal direction while communicating with the lower part of the plasma part and has a diameter smaller than the diameter of the plasma part and an internal volume for forming a buffy coat layer, and a cylindrical erythrocyte part which extends in the longitudinal direction while communicating with the lower part of the buffy coat part and has a diameter larger than the diameter of the buffy coat part and an internal volume for forming an erythrocyte layer, wherein the free end part of the plasma part and the free end part of the erythrocyte part are respectively opened; a lower packing movably accommodated in the erythrocyte part while maintaining an air-tight state; and a pusher moving the lower packing.